<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01960179</url>
  </required_header>
  <id_info>
    <org_study_id>SFY13476</org_study_id>
    <secondary_id>U1111-1134-2695</secondary_id>
    <nct_id>NCT01960179</nct_id>
  </id_info>
  <brief_title>Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes</brief_title>
  <official_title>An Open-label, Multicenter 24-Week And 52-Week Study Assessing The Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To assess the overall safety of lixisenatide once daily treatment in monotherapy over 24 and&#xD;
      52 weeks in patients with type 2 diabetes in Japan&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      To assess the effects of lixisenatide once daily treatment in monotherapy over 24 and 52&#xD;
      weeks on:&#xD;
&#xD;
        -  HbA1c (Glycated hemoglobin A1c) reduction;&#xD;
&#xD;
        -  Fasting plasma glucose;&#xD;
&#xD;
        -  Body weight.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Group 1: 60 weeks ± 11 days&#xD;
&#xD;
        -  Group 2: 32 weeks ± 7 days&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety over 24 and 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data.</measure>
    <time_frame>from baseline to 24 weeks and 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in HbA1c</measure>
    <time_frame>from baseline to week 24 and week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in fasting plasma glucose</measure>
    <time_frame>from baseline to week 24 and week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in body weight</measure>
    <time_frame>from baseline to week 24 and week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">361</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>lixisenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lixisenatide monotherapy by group (Group 1: 52-week treatment; Group 2: 24-week treatment)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lixisenatide AVE0010</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: Subcutaneous injection</description>
    <arm_group_label>lixisenatide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients with type 2 diabetes mellitus diagnosed for at least 2 months.&#xD;
&#xD;
          -  Not treated with anti-diabetic drug or treated with a stable dose of 1 oral&#xD;
             anti-diabetic drug (OAD) for at least 3 months prior to screening visit. Previous OAD&#xD;
             (if any) have to be stopped at Visit 1.1 to be washed out during the run-in period at&#xD;
             least for 6 weeks;&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  At screening&#xD;
&#xD;
          -  age &lt;20 years;&#xD;
&#xD;
          -  HbA1c &lt;7% or &gt;9.5% (for patients on OAD &lt;6.5% or &gt;8.5%);&#xD;
&#xD;
          -  fasting plasma glucose &gt;250 mg/dL (&gt;13.9 mmol/L);&#xD;
&#xD;
          -  Use of more than one OAD within 3 months prior to screening;&#xD;
&#xD;
          -  Use of Thiazolidinedione (TZD) within 6 months prior to screening;&#xD;
&#xD;
          -  Use of insulin within 3 months prior to screening; Note: Short time use (≤10 days) of&#xD;
             insulin due to acute illness or surgery (eg, infectious disease) is allowed.&#xD;
&#xD;
          -  Any previous treatment with lixisenatide (eg, participation in a previous study with&#xD;
             lixisenatide) or any other GLP-1 receptor agonist;&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  Women of childbearing potential with no effective contraceptive method;&#xD;
&#xD;
          -  Pregnancy or lactation;&#xD;
&#xD;
          -  Laboratory findings at the time of screening:&#xD;
&#xD;
        oAmylase and/or lipase &gt;3 times the upper limit of the normal laboratory range (ULN);&#xD;
&#xD;
          -  ALT &gt;3 ULN;&#xD;
&#xD;
          -  Calcitonin ≥20 pg/mL (5.9 pmol/L);&#xD;
&#xD;
          -  Positive serum pregnancy test in women of childbearing potential;&#xD;
&#xD;
          -  History of acute or chronic pancreatitis, pancreatectomy, stomach/gastric surgery,&#xD;
             inflammatory bowel disease;&#xD;
&#xD;
          -  Personal or immediate family history of medullary thyroid cancer (MTC) or genetic&#xD;
             conditions that predispose to MTC (eg, multiple endocrine neoplasia syndromes);&#xD;
&#xD;
          -  Allergic reaction to metacresol.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 392006</name>
      <address>
        <city>Adachi-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392005</name>
      <address>
        <city>Chiba-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392010</name>
      <address>
        <city>Chiyoda-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392004</name>
      <address>
        <city>Chuo-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392015</name>
      <address>
        <city>Chuo-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392003</name>
      <address>
        <city>Chuoh-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392012</name>
      <address>
        <city>Ebina-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392024</name>
      <address>
        <city>Higashiosaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392023</name>
      <address>
        <city>Kashiwara-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392008</name>
      <address>
        <city>Kawagoe-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392009</name>
      <address>
        <city>Kisarazu-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392002</name>
      <address>
        <city>Koganei-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392007</name>
      <address>
        <city>Koriyama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392011</name>
      <address>
        <city>Mitaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392025</name>
      <address>
        <city>Nagoya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392026</name>
      <address>
        <city>Nagoya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392013</name>
      <address>
        <city>Ogawa-Machi, Hikigun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392014</name>
      <address>
        <city>Ohta-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392022</name>
      <address>
        <city>Okawa-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392021</name>
      <address>
        <city>Osaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392028</name>
      <address>
        <city>Osaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392029</name>
      <address>
        <city>Osaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392030</name>
      <address>
        <city>Sapporo-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392018</name>
      <address>
        <city>Sendai-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392001</name>
      <address>
        <city>Shinjuku-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392020</name>
      <address>
        <city>Suita-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392017</name>
      <address>
        <city>Toshima-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392027</name>
      <address>
        <city>Toyonaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392016</name>
      <address>
        <city>Yokohama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392019</name>
      <address>
        <city>Yokohama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>September 27, 2013</study_first_submitted>
  <study_first_submitted_qc>October 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <last_update_submitted>April 8, 2015</last_update_submitted>
  <last_update_submitted_qc>April 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lixisenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

